|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fondaparinux#Adult Indications and Dosage]] |
| {{Fondaparinux}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Indications And Usage==
| |
|
| |
| ===Prophylaxis of Deep Vein Thrombosis===
| |
| ARIXTRA® is indicated for the prophylaxis of [[deep vein thrombosis]] (DVT), which may lead to [[pulmonary embolism]] (PE):
| |
|
| |
| :*In patients undergoing hip fracture surgery, including extended prophylaxis;
| |
| :*In patients undergoing hip replacement surgery;
| |
| :*In patients undergoing knee replacement surgery;
| |
| :*In patients undergoing abdominal surgery who are at risk for thromboembolic complications.
| |
|
| |
| ===Treatment of Acute Deep Vein Thrombosis===
| |
| ARIXTRA is indicated for the treatment of acute [[deep vein thrombosis]] when administered in conjunction with [[warfarin ]]sodium.
| |
|
| |
| ===Treatment of Acute Pulmonary Embolism===
| |
| ARIXTRA is indicated for the treatment of acute [[pulmonary embolism]] when administered in conjunction with [[warfarin ]]sodium when initial therapy is administered in the hospital.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref>
| |
|
| |
| ==References==
| |
| {{Reflist}}
| |
|
| |
| {{FDA}}
| |
| [[Category: Cardiovascular Drugs]] | | [[Category: Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category: Drug]] |
| | [[Category: Anticoagulants]] |